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BACE2 distribution in major brain cell types and
identiﬁcation of novel substrates
Iryna Voytyuk1,2, Stephan A Mueller3,4, Julia Herber3,4, An Snellinx1,2, Dieder Moechars5, Geert van Loo6,7 ,
Stefan F Lichtenthaler3,4,8,9, Bart De Strooper1,2,9,10
β-Site APP-cleaving enzyme 1 (BACE1) inhibition is considered one
of the most promising therapeutic strategies for Alzheimer’s
disease, but current BACE1 inhibitors also block BACE2. As the
localization and function of BACE2 in the brain remain unknown, it
is difﬁcult to predict whether relevant side effects can be caused
by off-target inhibition of BACE2 and whether it is important to
generate BACE1-speciﬁc inhibitors. Here, we show that BACE2 is
expressed in discrete subsets of neurons and glia throughout the
adult mouse brain. We uncover four new substrates processed by
BACE2 in cultured glia: vascular cell adhesion molecule 1, delta
and notch-like epidermal growth factor–related receptor, ﬁbro-
blast growth factor receptor 1, and plexin domain containing 2.
Although these substrates were not prominently cleaved by
BACE2 in healthy adult mice, proinﬂammatory TNF induced
a drastic increase in BACE2-mediated shedding of vascular cell
adhesion molecule 1 in CSF. Thus, although under steady-state
conditions the effect of BACE2 cross-inhibition by BACE1-directed
inhibitors is rather subtle, it is important to consider that side
effects might become apparent under physiopathological con-
ditions that induce TNF expression.
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Introduction
Currently, β-site APP-cleaving enzyme 1 (BACE1) is considered the
major therapeutic target for Alzheimer’s disease (AD) (Cole &
Vassar, 2007; Vassar et al, 2014; Yan & Vassar, 2014; Barão et al,
2016). Together with γ-secretase, it generates amyloid-β, a short
hydrophobic peptide that aggregates extracellularly into amyloid
plaques in the brain of AD patients (De Strooper et al, 1998; Vassar
et al, 1999; Hardy & Selkoe, 2002). Although the genetic evidence
strongly supports the targeting of γ-secretases (Szaruga et al, 2017;
Voytyuk et al, 2017) to lower amyloid-β generation in the brain of
patients, the severe side effects observed in phase 3 clinical trials
have brought γ-secretase research almost to an end (Doody et al,
2013; De Strooper, 2014). Alternatively, BACE1 inhibition strategies
have now taken center stage in the ﬁght against the disease, and
several potent, brain-penetrant compounds have entered phase 3
clinical trials (reviewed in Vassar et al, 2014; Barão et al, 2016). The
development and evaluation proceed cautiously as BACE1 can
cleave numerous other substrates besides amyloid precursor
protein (APP) (Kuhn et al, 2012; Zhou et al, 2012; Dislich et al, 2015).
These substrates have been linked to synaptic plasticity (Wiera &
Mozrzymas, 2015; Hu et al, 2016; Munro et al, 2016; Pigoni et al, 2016),
myelination (Hu et al, 2006; Willem et al, 2006; Fleck et al, 2013; Van
Bebber et al, 2013), and axonal outgrowth (Wright et al, 2007; Hitt
et al, 2012; Barão et al, 2015) among the most studied functions.
In addition, all available BACE1 inhibitors that are currently
tested in the clinic cross-inhibit BACE2, the close homologue of
BACE1 (Bennett et al, 2000; Farzan et al, 2000). Most of the inhibitors
are equipotent (Neumann et al, 2015; Cebers et al, 2016a), with MK-
8931 showing even higher selectivity for BACE2 (Kennedy et al, 2016).
Similar to BACE1, BACE2 is a type I transmembrane protein that
belongs to the peptidase A1 family (also called the pepsin family) of
aspartyl proteases. Unlike BACE1, which is highly expressed in the
brain, BACE2 is more prominently found in peripheral tissues,
namely, the colon, kidney, and pancreas (Bennett et al, 2000). In
pancreatic β cells, for example, BACE2 cleaves the pro-proliferative
plasma membrane protein TMEM27, thereby impacting β cell mass
and function (Esterha´zy et al, 2011). Furthermore, BACE2 suppres-
sion promotes β cell survival through another potential substrate,
islet amyloid polypeptide, whose overexpression induces glucose
tolerance defects (Rulifson et al, 2016; Alcarraz-Viza´n et al, 2017). In
this regard, inhibition of BACE2 has even been proposed for the
treatment of diabetes (Esterha´zy et al, 2011; Stützer et al, 2013).
BACE2 also processes the pigment cell–speciﬁc melanocyte protein
involved in melanosome formation in pigment cells (Rochin et al,
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2013). As a result, genetic knockout (KO) or pharmacological inhibition
of BACE2 results in depigmentation, the most obvious phenotype of
mouse Bace KO models and the most consistent side effect seen in
preclinical studies of BACE1/2 inhibition (Dominguez et al, 2005;
Shimshek et al, 2016; Cebers et al, 2016b; Voytyuk et al, 2017).
Thus, although some research has already indicated potential
problems with peripheral inhibition of BACE2, surprisingly little is
known about the function of BACE2 in the brain, the main target
organ for BACE1 inhibitors. Using a sensitive and very speciﬁc in
situ hybridization technique, we show here that Bace2 mRNA is
expressed in subsets of neurons, oligodendrocytes, and astrocyte-
like cells lining the lateral ventricles in the mouse brain. Although
all major cell types express Bace2, the levels vary considerably
within the cell types in different regions of the brain. Using liquid
chromatography coupled with tandem mass spectrometry (LC–MS/
MS) to analyze the conditioned medium of cultured mouse glia, we
uncover and validate four previously unknown substrates of Bace2:
vascular cell adhesion molecule 1 (VCAM1), delta and notch-like
epidermal growth factor–related receptor (DNER), ﬁbroblast growth
factor receptor 1 (FGFR1), and plexin domain containing 2 (PLXDC2).
We ﬁnd that under constitutive, nonstimulated conditions, the
extent of substrate cleavage by BACE2 is low. However, we dem-
onstrate that BACE2 cleavage of the new substrate VCAM1 gets
strongly up-regulated under inﬂammatory conditions in vitro and
in vivo. Neuroinﬂammation is one of the hallmarks of AD, and
several inﬂammatory cytokines, in particular TNF and IL-1β, are
known to be up-regulated in both the periphery and the brain of AD
patients (Akiyama et al, 2000; Sastre et al, 2006; Wang et al, 2015; Lai
et al, 2017). Our ﬁndings indicate that BACE2 may be an important
secretase under inﬂammatory conditions in the brain.
Results
Bace2 expression in the mouse brain
To characterize Bace2 expression in the brain and compare it with
that of Bace1, we used the RNAscope Fluorescent Multiplex Assay
(ACD Bio). This in situ hybridization technique uses 20 probe pairs
and four ampliﬁcation steps to allow quantitative detection of
a single RNA molecule with excellent sensitivity and speciﬁcity.
RNAscope in situ hybridization data show that Bace2 is less widely
expressed in the mouse brain than Bace1. Characterization of the
expression pattern and relative abundance in different brain areas
and cell types is summarized in Table 1 and examples of expression
patterns are shown in Fig 1. Synaptophysin (Syp), glutamate as-
partate transporter (Glast), and myelin basic protein (Mbp) were
used as speciﬁc markers for neurons, astrocytes, and oligoden-
drocytes, respectively, demonstrating that Bace2 expression can be
detected in all three cell types (Fig 1A–C). It is interesting that
Bace2 expression in these cells varies across different brain regions.
To evaluate the level of expression of our secretases of interest,
we compared them with markers and reference genes used by
RNAscope with known expression levels (Fig S1) (Zhang et al, 2014).
Highest neuronal expression is found in the mouse ventral hip-
pocampus at 4 mo (Fig 1D). The lining of the lateral ventricle is the
only brain area showing Bace2 expression in astrocytes (Fig 1E),
whereas in oligodendrocytes, especially in young animals, Bace2 is
found throughout the ﬁber tracts (Fig 1F). Although in most cases
Bace1 is expressed in Bace2-positive cells (Fig 1G), the reverse is not
true, as Bace1 is much more widely expressed in the brain. For
instance, Bace1 is abundant in neuronal-rich areas, such as the
hippocampus, thalamus, and cortex, showing much higher expres-
sion than Bace2. Many neurons, such as Purkinje cells, express only
Bace1 (Fig 1I), and there are whole neuron-rich areas, such as the
dorsal hippocampus, with high Bace1 expression, but virtually devoid
of Bace2 (Fig 1J). Some oligodendrocytes in the ﬁber tracts of the
striatum, cerebellum, and corpus callosum express both secretases,
with Bace1 being more abundant (Fig 1H). Interestingly, expression of
both Bace1 and Bace2 in oligodendrocytes is highest in young
postnatal day (P) 16 animals, at the age of myelination onset. Few
astrocytes throughout the brain focally express Bace1, whereas Bace2
is only expressed at the astrocytes lining the lateral ventricle (Fig 1K).
Identiﬁcation of Bace2 substrate candidates
As Bace2 is clearly expressed in various brain cell types, we set out
to uncover its substrates. Following the approach of a previous
study of BACE1 substrates in CSF (Dislich et al, 2015), we examined
mouse CSF with mass spectrometry, comparing the CSF of double
KO (dKO) mice with that of Bace1−/− mice (Fig S2 and Table S1).
Overall, 579 proteins were quantiﬁed in at least three replicates of





expression BACE1 expressing cell types
Hippocampus (dorsal) − Not found +++ Neurons
Hippocampus (ventral CA3 and subiculum) ++ Neurons +++ Neurons
Cortex (highest in motor and somatosensory layers 4
and 5) + Neurons ++ Neurons, occasional astrocytes
Thalamus + Neurons +++ Neurons, occasional astrocytes
Cerebellum + Oligodendrocytes ++ Neurons, oligodendrocytes
Striatum + Oligodendrocytes ++ Oligodendrocytes
Fiber tracts +, ++ at P16 Oligodendrocytes ++, +++ at P16 Oligodendrocytes, astrocytes
Lateral ventricle lining + Astrocytes − Not found
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both, Bace1−/− and dKO mouse CSF. A subset of 60 proteins showed
a log2-transformed ratio of at least ±0.5 (>1.41-fold or <0.71-fold)
with P-value < 0.05 (Table S1). The analysis demonstrated pro-
nounced increases and decreases in cytosolic proteins such as
IGAC, SERPINA3M, IGHG1, IGG2AC and SCG5, LY86, OGN, and C2 (Fig
S2). Among the increased proteins, we found proteins of the im-
munoglobulin family and a member of the serpin family of serine
protease inhibitors, whose functions are not clearly understood
(Silverman et al, 2001). The decreased proteins are a neuroendo-
crine member of the secretogranin family, a player in the innate
immune response, small leucine-rich proteoglycan, and members
of the complement system (Taupenot et al, 2003; Deckx et al, 2016;
Hasan et al, 2017). However, as none of these proteins harbors
a transmembrane domain, they are unlikely to be direct BACE2
substrates, and the observed changes are likely due to the indirect
effects of BACE2 absence (in the background of Bace1−/−). Single-
span transmembrane proteins LRRN1, PLXDC2, CNTN2, and PTPRN2
that were previously identiﬁed as BACE1 substrates are given in
bold in Fig S2 (Kuhn et al, 2012; Zhou et al, 2012; Dislich et al, 2015);
they are likely direct BACE2 substrates as well, but are only partially
cleaved by BACE2 (31–51% decreases reﬂect BACE2 contribution on
top of BACE1 inhibition). This demonstrates that BACE2 inactivation
alters BACE2 substrate levels in the murine CSF proteome.
Proteins in CSF may originate from all brain cell types. As shown
in Fig 1, these express highly variable levels of BACE2 (Table 1). Thus,
we further examined BACE2 substrate candidates with brain rele-
vance by turning to a primary cell culture, where BACE2 was pre-
viously shown to be expressed and active (Dominguez et al, 2005).
Glia were cultured in the presence or absence of the unselective
inhibitor Compound J (CpJ), which blocks both BACE1 and BACE2.
Figure 1. Bace2 mRNA expression in neurons,
astrocytes, and oligodendrocytes.
Examples of Bace2 mRNA expression in neurons (A),
astrocytes (B), and oligodendrocytes (C) as identiﬁed
by co-localized cell type–speciﬁc markers Syp, Glast,
and Mbp, respectively. Brain areas with highest
neuronal (D), astrocyte (E), and oligodendrocyte (F)
expression of Bace2. Neurons (G), as well as
oligodendrocytes (H), expressing Bace2 also express
Bace1. Purkinje cells express only Bace1 (I); similarly,
dorsal hippocampus shows high Bace1 expression,
but is virtually devoid of Bace2 (J). Few astrocytes
throughout the brain focally express Bace1, whereas
Bace2 is only expressed by astrocytes lining the lateral
ventricle (K). Representative images from two adult
(4 mo) and two young (P16–20) male WT mice. Syp,
neuronal marker; Glast, astrocytic marker; and Mbp,
oligodendrocyte marker.
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Therefore, we decided to increase the sensitivity of our system by using
Bace1−/− glia to identify proteins selectively shed by BACE2. For this
purpose, we used a mass spectrometry–based screening method.
Conditioned media of cultures treated with an inhibitor or vehicle only
were collected after 48 h. Glycosylated membrane proteins, which
constitute nearly 90% of all single-span membrane proteins, were
enriched using the secretome protein enrichment with click sugars
method, andproteinswere quantiﬁed by using LC–MS/MS–based label-
free quantiﬁcation (LFQ) (Kuhn et al, 2012). Overall, 246 proteins (191
glycoproteins according to UniProt) were relatively quantiﬁed in three
replicates and subjected to statistical analysis (Fig 2B and C). Six sig-
niﬁcantly decreased proteins were identiﬁed by mass spectrometry
analysis in a conditioned medium of primary glia cultures treated with
an inhibitor, four of which were decreased by more than 30%: VCAM1,
DNER, FGFR1, and PLXDC2 (Fig 2A and Table S2). All four are, furthermore,
type 1 transmembrane proteins, with large extracellular domains with
several predicted glycosylation sites (Fig 2D). Only peptides matching
the extracellular domains were identiﬁed (Fig 2D), which indicates that
these proteins were indeed secreted. The shedding of VCAM1 and DNER
was very strongly reduced by 80% and 73%, respectively, suggesting that
BACE2 is the main protease cleaving these proteins, with little contri-
bution of other “sheddases” in the glia. FGFR1 and PLXDC2 shedding is,
in contrast, only moderately reduced by 48% and 35%, respectively,
suggesting that other proteases are likely contributing to their cleavage.
Validation of BACE2 substrate candidates in cell culture
The results of themass spectrometry–based screening were further
validated in cell cultures. Speciﬁc antibodies for the N-terminal
part of VCAM1 and DNER are readily available, allowing their vali-
dation as substrates at the endogenous levels of expression. As
shown in Fig 3A, shed VCAM1 is detected in a conditionedmedium of
Bace1−/− glia, and this shedding is decreased by 64% upon in-
hibition with CpJ (Fig 3A and B). The full-length VCAM1 shows a slight
trend to accumulate in the glia cells without reaching statistical
signiﬁcance (Fig 3A and C). Prominent VCAM1 shedding is observed
in WT and Bace1−/− glia, whereas little shedding is seen in Bace2−/−
glia (Fig 3D). We next used the Bace inhibitor CpJ in Bace1−/−, WT, and
Bace2−/− glia to determine the effect on VCAM1 shedding. Similar to
Bace1−/− glia, shedding of VCAM1 is attenuated in WT glia upon BACE
inhibition (Fig 3E), whereas no change is observed in the already low
level of shedding in Bace2−/− glia (Fig 3F), suggesting that VCAM1 is
a selective BACE2 substrate in glia cells and not processed by
BACE1.
DNER shedding into the medium is decreased by 75% upon
treating the cells with CpJ (Fig 3G and H). Full-length DNER does not
accumulate in the glia cells (Fig 3G and I). DNER is shed byWT glia, as
well as Bace1−/− glia, but shedding is prominently decreased in
Bace2−/− glia (Fig 3J). CpJ treatment dramatically decreases the
shedding of DNER in WT and Bace1−/− glia (Fig 3G and K), but does
not further decrease shedding of DNER in Bace2−/− glia cultures (Fig
3L).
Unfortunately, available antibodies for FGFR1 and PLXDC2 cross-
react with a variety of proteins when used at the endogenous levels
of expression. We, therefore, moved to a COS-1 overexpression
system. Shedding of tagged murine PLXDC2 overexpressed in COS-1
cells can bemonitored, and commercially available antibody raised
against N-terminal FGFR1 detects the high levels of the human
Figure 2. BACE2 secretome in primary glia cultures.
(A) Volcano plot of proteomic analysis of conditioned
medium from Bace1−/− cultured glia treated with BACE
inhibitor CpJ or vehicle (n = 3). For each relatively
quantiﬁed protein (representing a dot on the plot), the
−log10-transformed t test P-value was plotted against
the log2-transformed LFQ intensity ratios of CpJ/
vehicle. Proteins with a t test P-value <0.05 are
marked with open red circles, whereas proteins with
P-value >0.05 are shown in blue. Closed red dots
labeled with bold letters denote the four substrate
candidates that are reduced by more than 30% in the
inhibitor-treated samples. No corrections for multiple
hypothesis testing were applied in this discovery
experiment. (B) Uniprot subcellular locations of the
identiﬁed proteins. Glycoproteins were deﬁned
according to UniProt Keywords. (C) Topology of
membrane proteins according to Uniprot subcellular
locations. (D) Uniprot Topology of DNER, FGFR1, PLXDC2,
and VCAM1 with mapped identiﬁed peptides.
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overexpressed protein. Full-length FGFR1 overexpressed in COS-1
cells runs as a doublet around the 97-kD mobility marker (Fig 4A).
When FGFR1 is co-expressed in COS-1 cells with human BACE1 or
BACE2, a fragment between 51 and 64 kD is shed into the medium,
and this is inhibited by CpJ. Thus, shedding of this fragment into
the medium can be performed by both BACE2 and BACE1 in this
overexpression experiment. A shed triple band running as a smear
around 40 kD is only seen upon co-expression of FGFR1 with BACE2
and may represent degradation products. In fact, these bands are
not seen after CpJ treatment, indicating that it is indeed BACE2
activity that is initially responsible for their production and that
likely other proteases can then further cleave the shed FGFR1.
FGFR1 is likely processed by additional endogenous proteases as
several additional bands appear when FGFR1 is transfected
alone. It is also possible that these bands are overexpression
artifacts. Thus, our transfection data conﬁrm that FGFR1 can be
processed by both BACE1 and BACE2, resulting in a shed fragment
with similar mobility in SDS–PAGE and various other fragments.
In the absence of good antibodies, it is impossible to explore the
physiological relevance of these cleavages further.
Transfected mouse PLXDC2 (N-terminally tagged with HA and
C-terminally tagged with FLAG) appeared in the lysate between 64
and 97 kD as two bands, likely lower immature and upper glyco-
sylated forms (Fig 4B), but it is this mature glycosylated form that is
apparently processed by BACE1 or BACE2 as it disappears upon co-
expression. Concomitantly, a shed fragment is observed above the
64-kD mark in the conditioned medium and this is increased with
BACE1 or BACE2 co-expression. Shedding of PLXDC2 and disap-
pearance of the mature form of PLXDC2 in the cell extracts are
inhibited by CpJ. These overexpression data conﬁrm that PLXDC2
can be processed by BACE2 (and BACE1) but do not yield further
physiological information on the relevance of this processing
event. However, this work awaits the generation of high-quality
antibodies.
Figure 3. Validation of VCAM1 and DNER as BACE2
substrates in primary mixed glia cultures.
(A) VCAM1 in medium and cell lysates of Bace1−/− glia
treated with vehicle or CpJ (10 μM) for 24 h (n = 4).
(B) Quantiﬁcation of VCAM1 shedding into conditioned
medium of Bace1−/− glia treated with vehicle or CpJ for
24 h (paired t test, P = 0.01, n = 4). (C) Quantiﬁcation of
VCAM1 accumulation in cell lysates of Bace1−/− glia
treated with vehicle or CpJ (10 μM) for 24 h (paired t test,
P = 0.08, n = 4). (D) VCAM1 shedding in WT, Bace1−/−, and
Bace2−/− glia (n = 3). (E) VCAM1 in medium and cell
lysates of WT glia treated with vehicle or CpJ (10 μM) for
24 h (n = 3). (F) VCAM1 in medium and cell lysates of
Bace2−/− glia treated with vehicle or CpJ (10 μM) for 24 h
(n = 3). (G) DNER in medium and cell lysates of Bace1−/−
glia treated with vehicle or CpJ (10 μM) for 24 h (n = 3).
(H) Quantiﬁcation of DNER shedding into conditioned
medium of Bace1−/− glia treated with vehicle or CpJ for
24 h (paired t test, P = 0.03, n = 3). (I) Quantiﬁcation of
DNER accumulation in cell lysates of Bace1−/− glia
treated with vehicle or CpJ for 24 h (paired t test, P = 0.3,
n = 3). (J) DNER shedding in WT, Bace1−/−, and Bace2−/−
glia (n = 3). (K) DNER in medium and cell lysates of WT
glia treated with vehicle or CpJ (10 μM) for 24 h (n = 3).
(L) DNER in medium and cell lysates of Bace2−/− glia
treated with vehicle or CpJ (10 μM) for 24 h (n = 3).
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Validation of Bace2 substrate candidates in vivo
Because both VCAM1 and DNER were validated as authentic BACE2
substrates at the endogenous level in cultured glia cells, and good
antibodies are available, we proceeded with their validation in CSF
from WT, Bace1−/−, Bace2−/−, and dKO mice. The shedding of DNER
and VCAM1 was compared with that of a well-known BACE1 sub-
strate, SEZ6 (Dislich et al, 2015; Pigoni et al, 2016) (Fig 5A). As ex-
pected, the shedding of SEZ6 was signiﬁcantly decreased in the CSF
of Bace1−/− and dKOmice but not in Bace2−/− (Fig 5A and B), whereas
no signiﬁcant differences in DNER and VCAM1 were observed
between genotypes (Fig 5C and D, respectively). Similarly, no
differences were observed in soluble DNER in the TBS fraction of
homogenized cortices from 1-year-old male mice of different
genotypes (Fig S3A and B), as well as in soluble VCAM1 in TBS
fractions (Fig S3C and D). The levels of full-length proteins were
found to be equal as well (Fig S3E and F). Similar results were
obtained using the subdissected ventral hippocampus of 4-mo-
old males (Fig S3G) and P16 subventricular zone (Fig S3H), brain
areas where high BACE2 expression is observed. Finally, to rule
out any potential compensation mechanisms occurring in vivo in
KO animals, an acute inhibition experiment was performed in
4-mo-old Bace1−/− males treated with CpJ by 4× i.p. injections at
12-h intervals. No changes in VCAM1 or DNER processing were
observed (Fig S3I and J, respectively). Therefore, we conclude
that under basal conditions, VCAM1 and DNER are not shed by
BACE2 in the brain.
We reasoned that cultured glia, where we identiﬁed the four new
BACE2 substrates, are not well representative of glia found in the
adult mouse brain in basal conditions (Cahoy et al, 2008; Lange
et al, 2012; LoVerso et al, 2015). As astrocytes become activated
during injury, primary culture preparation from dissected brain
might reﬂect a certain degree of inﬂammatory phenotype (Lange
et al, 2012). Interestingly, the level of one of the BACE2 substrates
identiﬁed, VCAM1, is up-regulated upon inﬂammatory stimulus
in vitro and in vivo (van Loo et al, 2006). When we added pro-
inﬂammatory agents TNF or IL-1β to primary glia cultures, we ob-
served the expected up-regulation of VCAM1 and, remarkably,
a strong increase in VCAM1 shedding into the medium, in particular
at the 24-h time point (Fig 6A). This additional shedding is per-
formed by BACE2, as CpJ treatment of TNF-treated Bace1−/− glia
blocked the increased shedding evenwhen VCAM1 is up-regulated (Fig
6B). Notably, this effect of pro-inﬂammatory agents is speciﬁc for
VCAM1 and, in contrast, leads to a down-regulation of DNER in the
lysates of glia treated with TNF and IL-1β (Fig S4). Soluble DNER in the
medium is already at the borderline of detection, and there are no
indications of any change upon pro-inﬂammatory treatments (Fig S4).
Subsequently, we treated WT mice with 250 μg/kg TNF for 24 h, as
was previously described to induce neuroinﬂammation (Biesmans
et al, 2015). Shed VCAM1 was increased 2.2-fold =in the CSF of mice
treated with TNF (Fig 6C and D). Surprisingly, we did not observe any
increase in VCAM1 in either the TBS fraction or total cell lysates of brain
homogenates (Fig 6C). We ﬁnally compared the responses to TNF inWT,
Bace1−/−, and Bace2−/−mice and found that bothWT and Bace1−/−mice
show up-regulated VCAM1 shedding into CSF upon 24-h treatment with
TNF, whereas VCAM1 shedding in Bace2−/− mice is not affected (Fig 6E
and F). Thus, BACE2 is responsible for the additional shedding of VCAM1
in pro-inﬂammatory conditions in vitro and in vivo.
Discussion
The role of BACE2 in the pancreas and skin is generally recognized
(Esterha´zy et al, 2011; Rochin et al, 2013; Shimshek et al, 2016), but
Figure 4. Validation of FGFR1 and PLXDC2 as BACE2
substrates in COS-1 overexpression system.
(A) FGFR1 in lysates and medium of COS-1 cells
overexpressing FGFR1 alone (lane 2), FGFR1 with BACE1
(lanes 3 and 4), and FGFR1 with BACE2 (lanes 5 and 6).
Lanes 4 and 6 were treated with inhibitor CpJ (10 μM).
Lane 1 was mock-transfected with an empty vector.
Representative for three experiments. (B) PLXDC2 in
medium (top panel) and lysates (second panel from
the top) of COS-1 cells overexpressing PLXDC2 alone
(lane 2), PLXDC2 with BACE1 (lanes 3 and 4), and PLXDC2
with BACE2 (lanes 5 and 6). Lanes 4 and 6 were treated
with inhibitor CpJ (10 μM). Lane 1 was mock-transfected
with an empty vector. Control blots for BACE1, BACE2,
and actin are shown for each transfection.
Representative for three experiments.
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despite its relevance for AD therapy, very little is known about
BACE2 expression and function in the central nervous system (CNS).
Here, we show that Bace2mRNA is present in subsets of neurons, in
oligodendrocytes, and in some cells expressing the astrocyte
marker Glast and lining the lateral ventricle (Fig 1). Their localization
in the subventricular zone suggests that they are astrocyte-like
neural stem cells (Kokovay et al, 2010), which are known to express
VCAM1 (Kokovay et al, 2012). Recent single-cell sequencing shows
Bace2 expression mainly in oligodendrocytes (Zhang et al, 2014),
and in subsets of neurons and astrocytes (Zeisel et al, 2015), in
agreement with our in situ hybridization experiments. In our study,
the highest expression levels of Bace2 mRNA are seen in oligoden-
drocytes of the ﬁber tracts in young mice and in neurons of the
ventral hippocampus in adult animals. In comparison, the expression
pattern of Bace1 is much wider with many neurons of the CNS, even
those devoid of Bace2, displaying Bace1 mRNA, in line with previous
conclusions that it is the predominant β-secretase in the brain (Cai
et al, 2001; Vassar et al, 2014; Barão et al, 2016). Given the overlapping
expression of Bace2 with Bace1 in neurons and oligodendrocytes, it
seems logical to speculate on the redundancy of the two enzymes.
Both secretases can indeed cleave similar substrates like APP
(Dominguez et al, 2005; Bettegazzi et al, 2011), as well as PLXDC2
(Dislich et al, 2015) and FGFR1, which was shown in this study.
However, as we will discuss in the following paragraphs, our data also
point toward speciﬁc processing of VCAM1 (in vitro and in vivo) and
DNER (in vitro primary cultures) exclusively by BACE2.
Having established the particular expression pattern of Bace2 in the
brain, we wondered whether there were any speciﬁc substrates for
BACE2 that could further shed light on its function in the CNS. We
focusedour attentionﬁrst on theCSF anddecided to comparematerial
from dKO (Bace1−/− and Bace2−/−) with single Bace1−/− mice. As shown
in Fig S2, the differences observed in transmembrane proteins were
small and, actually, the strongest changes were up-regulated proteins
without transmembrane domains, making them very unlikely BACE2
substrate candidates. Thus, in contrast to BACE1 deﬁciency (Dislich
et al, 2015), additional depletion of BACE2 did not reveal major BACE2
substrates secreted into the CSF.
We turned to mixed primary glia cultures, where BACE2 was
shown to be active (Dominguez et al, 2005). As shown in Fig 2A, we
identiﬁed four novel BACE2 substrates, namely, VCAM1, FGFR1, DNER,
and PLXDC2, the latter two previously reported as BACE1 substrates
in other cell types and mouse CSF (Kuhn et al, 2012; Zhou et al, 2012;
Stützer et al, 2013; Dislich et al, 2015). VCAM1 and DNER secretion was
strongly reduced in Bace2−/− cells and addition of the BACE inhibitor
CpJ to WT or Bace1−/− glia inhibited their secretion, indicating that
their processing is mainly performed by BACE2 in these cells (Fig 3).
The evidence that FGFR1 and PLXDC2 are BACE2 substrates is more
circumstantial. As no antibodies were available for FGFR1 and
PLXDC2 that detect their expression at the endogenous level, we
had to rely on overexpression systems to prove that BACE2, as well
as BACE1, can process both (Fig 4).
VCAM1 mediates the adhesion of white blood cells to the vas-
cular endothelium, thereby allowing immune cells to inﬁltrate
through blood vessels (Barreiro et al, 1998). It is also involved in
leukocyte homing during atherosclerosis (Gamrekelashvili &
Limbourg, 2016). In the brain, VCAM1 is found at high levels in
astrocytes (Zhang et al, 2014) and is also expressed by type B
neuronal stem cells at the rodent subventricular zone, where it
helps maintain the rosette arrangement of these cells and regu-
lates their lineage progression (Kokovay et al, 2012). DNER is
a transmembrane protein that mediates Notch signaling through
cell–cell interactions in neurons (Eiraku et al, 2002; Saito &
Takeshima, 2006). It is involved in the maturation of Bergman
glia (Eiraku et al, 2005; Saito & Takeshima, 2006). DNER has pre-
viously been identiﬁed as a BACE1 substrate in pancreatic β cells
(Stützer et al, 2013) and neurons (Kuhn et al, 2012), so it is surprising
that in cultured glia cells it is not shed by BACE1, but rather ex-
clusively by BACE2 (Fig 3J and L). According to recent RNAseq da-
tabases, Dner mRNA is expressed in oligodendrocyte precursor
cells and astrocytes, as well as neurons (Zhang et al, 2014; Zeisel
et al, 2015), and may have distinct functions in the different cell
types.
FGFR1 is involved in signaling pathways of a variety of cells. In the
mouse brain, it is expressed at high levels in astrocytes, as well as in
Figure 5. Absence of effects on VCAM1 and DNER in
CSF of Bace2/2 mice.
(A) Shed VCAM1 and DNER in triplicates of CSF of 11-mo-
old WT, Bace1−/−, Bace2−/−, and dKO male mice, as
compared with a known BACE1 substrate—SEZ6. (B)
SEZ6 is signiﬁcantly reduced in Bace1−/− and dKO, but
not Bace2−/− CSF compared with control WT CSF (one-
way ANOVA: P = 0.006, P = 0.008, and P = 1.00,
respectively; n = 3). (C) One-way ANOVA revealed no
signiﬁcant differences between shed DNER in Bace1−/−,
Bace2−/−, and dKO CSF, as compared with WT (P = 1.00,
P = 1.00, and P = 0.77, respectively; n = 3). (D) No
signiﬁcant differences were seen between shed VCAM1
in Bace1−/−, Bace2−/−, dKO, and WT CSF by one-way
ANOVA (P = 0.76, P = 1.00, and P = 1.00, respectively; n = 3).
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oligodendrocyte precursor cells (Zhang et al, 2014). PLXDC2 is a
transmembrane receptor for the multifunctional pigment epithelium-
derived factor important for neural growth, stem cell development,
angiogenesis, and cancer cell growth, among other functions
(Cheng et al, 2014). PLXDC2 is amitogen and increases neurogenesis,
resulting in thickening of the neural tube at the early stages of
development (Miller et al, 2007; Miller-delaney et al, 2011). In-
terestingly, PLXDC2 was previously identiﬁed as a BACE1 substrate in
human epithelial cell lines stably expressing BACE1 (Hemming et al,
2009), and its secretion is also affected by BACE1 deletion in mouse
CSF (Dislich et al, 2015). In addition, PLXDC2 was identiﬁed as
a BACE1 substrate in primary mouse neurons in two independent
studies (Kuhn et al, 2012; Zhou et al, 2012).
As indicated, we did not see any major changes in shed proteins
in the CSF by genetic inactivation of Bace2 on top of Bace1 (Fig S2).
We revaluated the effect on the secretion of the two major BACE2
substrates identiﬁed in the primary cell culture, that is, VCAM1 and
DNER, for which, coincidentally, good antibodies were also avail-
able. As shown in Figs 5 and S3, we did not see any effects on these
twomajor BACE2 substrates in vivo, in agreement with our unbiased
proteome analysis (Fig S2), suggesting that VCAM1 and DNER are not
prominently shed by BACE2 at baseline conditions in vivo in the
brain.
Interestingly, the most prominent substrate of BACE2, VCAM1, is
known to be up-regulated during inﬂammation (van Loo et al, 2006).
We conﬁrmed this in our Bace1−/−mixed glia culture and found that
further increase of inﬂammation in response to TNF or IL-1β ad-
ditionally increased the amount of VCAM1 secreted into the media
(Fig 6A). The increase was inhibited with the BACE inhibitor CpJ
(Fig 6B), conﬁrming that additional shedding was indeed BACE2-
dependent. Of note, the increase is likely a consequence of increased
VCAM1 expression, and not necessarily caused by direct effects on
BACE2 expression and/or activity (Fig 6A). We next evaluated
whether we could detect BACE2 processing of VCAM1 under in-
ﬂammatory conditions in vivo. We treated mice for 24 h with TNF,
adapting a protocol previously used to induce inﬂammation in
mouse brain (Biesmans et al, 2015). To our surprise, TNF treatment
resulted in a strong up-regulation of VCAM1 in the CSF of WT and
Bace1−/− animals, but did not have an effect on VCAM1 shedding in
Bace2−/− mice.
Figure 6. Validation of substrate under pro-
inﬂammatory challenge in vitro and in vivo.
(A) VCAM1 in medium and lysates of primary mixed
glia culture treated with murine recombinant TNF
(10 ng/ml) or IL-1β (10 ng/ml) for 8 h and 24 h (n = 3).
Control blots for BACE1, BACE2, and actin are shown.
(B) VCAM1 in medium and lysates of primary mixed glia
cells treated with murine recombinant TNF (10 ng/ml)
for 24 h, or treated with vehicle or CpJ inhibitor (10 μM)
(n = 3). Control blots for GFAP and actin are shown.
(C) VCAM1 in triplicates of CSF, TBS fraction, and total
cell lysates of cortices from 11-mo-old WT male controls
injected with PBS or treated with 250 μg/kg TNF. Actin
is used as a loading control. (D)VCAM1 shedding into CSF is
up-regulated upon TNF treatment (unpaired t test,P = 0.04;
n = 3), whereas no changes are observed in full-length
VCAM1 or soluble VCAM1 in TBS fraction shown in (C).
(E) VCAM1 in triplicates of CSF of 11-mo-old WT or Bace2−/−
mice treated with saline or 250 μg/kg TNF (top panel) and
VCAM1 in triplicatesof CSFof 11-mo-oldBace1−/−orBace2−/−
mice treated with saline or 250 μg/kg TNF (bottom panel).
(F) Two-way ANOVA reveal signiﬁcant differences in shed
VCAM1 between treated and untreated WT and Bace1−/−
mice (P = 0.0004 and P = 0.005, respectively; n = 3), but no
signiﬁcant differences in shed VCAM1 between treated and
untreated Bace−/− mice (P = 0.69).
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This intriguing result not only validates VCAM1 as an exclusive
and physiologically relevant BACE2 substrate, but also implicates
BACE2 in an inﬂammatory response pathway. Interestingly, VCAM1 is
up-regulated upon injury not only in rat brains (Zhang et al, 2015),
but also peripherally in AD patients (Lai et al, 2017) and increases in
the CSF with age (Li et al, 2017). This suggests that similar mech-
anisms of inﬂammation-induced up-regulation of VCAM1 are rel-
evant in humans. Further work, however, is needed to understand
the exact implications of VCAM1 shedding by BACE2 under such
conditions. Nonetheless, this work suggests that BACE2 function will
only become apparent under speciﬁc stress conditions, explaining
why until now so little effects at the phenotypic level have been
described in BACE2-deﬁcient animals.
An important lesson is to be deduced from these observations
for the ongoing BACE1/2 inhibitor clinical trials. Our data predict
that side effects caused by BACE2 cross-inhibition in the brain are
not going to become apparent under steady-state conditions.
However, BACE inhibitors are likely to be given for many years to
patients and it is difﬁcult to know what long-term effects chronic
suppression of VCAM1 and other BACE2 substrates might cause. One
should also take into account that AD is accompanied by CNS and
maybe peripheral inﬂammatory alterations. It might be useful to
measure VCAM1 as a marker for inﬂammation, as well as BACE2
activity, in the CSF and plasma of patients during the clinical trials.
Materials and Methods
Animals
The following mouse strains were used in this study: wild-type (WT)
C57BL/6J@Rj (Janvier Labs), Bace1−/− (Dominguez et al, 2005),
C57BL/6-Bace2<tm1.2> (Bace2−/−) (RIKEN Brain Science Institute),
and double Bace1−/− Bace2−/− KO (dKO) mice (Dominguez et al,
2005). The dKO mouse line was produced by breeding the afore-
mentioned Bace1−/− mice and Bace2ΔE6 mice, which harbor a de-
letion of exon 6 of Bace2 that contains the active site of the enzyme.
The RIKEN Bace2−/− mice used in this study lack the BACE2 protein
completely. All the strains are on a C57BL/6 background and were
maintained on a 12/12-h light–dark cycle with ad libitum food and
water. All experiments were approved by the ethics committee of
the University of Leuven and performed in accordance with the
Belgian and European Union regulations.
Multiplex ﬂuorescent in situ hybridization (RNAscope)
In situ hybridization was performed using the RNAscope Fluores-
cent Multiplex Assay (ACD Bio) according to the manufacturer’s
instructions. Brieﬂy, whole hemispheres of WT adult (4 mo) or WT
young (P16–P20) mouse brains were frozen in molds ﬁlled with
optimum cutting temperature (OCT) embedding matrix (Tissue-
Tek). Then, 14- to 16-μm sections were prepared on Superfrost Plus
slides (Thermo Fisher Scientiﬁc) using the NX70 cryostat (Thermo
Fisher Scientiﬁc). The sections were ﬁxed in 4% PFA and dehydrated
using a series of ethanol dilution steps. Protease digestion was
carried out for 20 min at RT using Pretreat 4 for fresh frozen tissue
provided in the RNAscope kit. Hybridization proceeded for 2 h at
40°C. The following probes were used: mBace1-C2, mBace2-C1,
mSyp-C3 (neuronal marker), mGlast-C3 (astrocyte marker), and
mMbp-C3 (oligodendrocyte marker). Brain-speciﬁc housekeeping
genes mPolr2a, mPpib, and mUbc were used as high-, medium-,
and low-expressing positive control probes, respectively. Bacterial
DapB probe was used as a negative control. Probe detection was
performed using the four ampliﬁcation reagents provided in the
RNAscope kit. Images were acquired using the Leica SP8× confocal
microscope and analyzed using the ImageJ software.
Mouse CSF collection
CSF was extracted from WT, Bace1−/−, Bace2−/−, and dKO mice
according to a previously described protocol (Liu & Duff, 2008) with
minor adjustments. A mixture of ketamine (100 mg/kg) and xylazine
(10 mg/kg) in PBS was administered intraperitoneally to anes-
thetize the mice. The animal was placed on a heating pad and
secured in the stereotaxic instrument with the head of the animal
held at a 135° angle. Hair on the head of the mouse was moved
aside and held by Duratears cream and the skin of the head and
neck overlying the cisterna magna was cut. Muscles and sub-
cutaneous tissue were gently pulled aside and secured using re-
tractors to reveal the triangular cisterna magna. The surgical ﬁeld
was cleaned from any blood, wiped three times with PBS, and dried
if necessary. The dura was punctured with a pulled glass capillary
(Sutter Instrument) attached to a syringe by tubing. The CSF was
collected from the cisterna magna by applying negative pressure
and transferred into a 0.5-ml LoBind tube (Eppendorf). Following
a centrifugation step at 1,500 g for 10 min, clean CSF was transferred
to a fresh tube and frozen at −80°C until analysis.
Primary glia culture and Bace inhibition experiments
All cell culture media, PBS, HBSS, trypsin, and supplements were
purchased from Invitrogen. Glia cultures were prepared from P3
mouse pups. Brieﬂy, the cortices were cleared from meninges, cut
into small pieces, digested by trypsin, and ﬁltered through a 70-μm
ﬁlter, and cells from two pups were plated on 6-cm uncoated petri
dishes. Glia cultures were maintained in MEM with Earle’s salt and
L-glutamine, 12.5% FBS, 0.6% glucose, and pen-strep. Once con-
ﬂuent, each 6-cm dish was frozen in 1 ml freezing medium (90% FBS
and 10% DMSO) to establish a frozen stock of glia. For Bace in-
hibition, a previously characterized small molecule CpJ was used,
which is an aminodihydrothiazine derivative inhibiting both BACE1
and BACE2 secretases (Kobayashi et al, 2007; Stützer et al, 2013).
Sample preparation for LC–MS/MS analysis
CSF samples (6 Bace1-/-, 5 dKO) were processed as previously
described (Pigoni et al, 2016). Brieﬂy, 5 μl CSF was alkylated using
dithiothreitol (Biomol) and iodoacetamide (Sigma-Aldrich). Pro-
teolytic digestion was performed by using 0.1 μg LysC (Promega) for
4 h and subsequently 0.1 μg trypsin (Promega) for 16 h at RT in the
presence of 0.1% (w/v) sodium deoxycholate (Sigma-Aldrich).
Deoxycholate was removed after acidiﬁcation by centrifugation
(16,000 g, for 10 min at 4°C). Peptides were puriﬁed and desalted
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using C18 stop and go extraction (Rappsilber et al, 2003). For LC–MS/
MS analysis, the peptides were dissolved in 20 μl 0.1% formic acid
(FA).
For proteomics experiments, eight vials of frozen stock Bace1−/−
glia (representing 16 animals) were plated in 10 × 10-cm petri dishes
(Fig S5A). All dishes were labeled with Click-IT ManNAz Metabolic
Glycoprotein Labeling Reagent (Life Technologies). Five dishes were
treated with 10 μM CpJ, whereas the remaining ﬁve were treated
with 20% Captisol vehicle as control, for 48 h in 5% FBS-containing
medium. Conditioned medium was collected, ﬁltered through a
0.45-mm PVDF ﬁlter (Millex), and concentrated using 30-kD Amicon
Ultracel Centrifugal ﬁlters (Millipore). The proteomics experiment
was repeated three times using independent cultures each time.
The secretome protein enrichment with click sugars was used
for sample preparation of conditioned cell culture medium
from vehicle and CpJ-treated glial cells as previously described
(Kuhn et al, 2012). This protocol facilitates the enrichment of
metabolic-labeled glycoproteins in the presence of serum proteins.
Brieﬂy, azide-labeled protein glycans were biotinylated with
dibenzylcyclooctyne–PEG4–biotin (DBCO–PEG4–biotin) conjugate
(Jena Bioscience) using click chemistry. The biotinylated glyco-
proteins were pulled down using high-capacity streptavidin aga-
rose (Thermo Fisher Scientiﬁc). The proteins were eluted from the
beads in 150 μl Laemmli buffer supplemented with 8 M urea and
3mM biotin at 95°C for 5 min. Proteins were separated by SDS–PAGE
(10%). Coomassie staining was used to visualize the proteins. Each
lane was cut into 14 fractions excluding the albumin band at 60 kD.
The gel slices were subjected to protein in-gel digestion using
150 ng of trypsin (Promega) per slice (Shevchenko et al, 2007). After
peptide extraction, the samples were dried using vacuum centri-
fugation. For LC–MS/MS analysis, the peptides were dissolved in
20 μl 0.1% FA.
LC–MS/MS analysis
An Easy nLC-1000 (Thermo Fisher Scientiﬁc) equipped with a col-
umn oven (Sonation) online coupled via a nano-electrospray ion
source (Thermo Fisher Scientiﬁc) to either a Q-Exactive or a Velos
Pro Orbitrap Mass Spectrometer (Thermo Fisher Scientiﬁc) was
used for LC–MS/MS analysis. Peptides were separated on a self-
packed C18 column (300 mm × 75 μm, ReproSil-Pur 120 C18-AQ,
1.9 μm, Dr. Maisch GmbH HPLC) using a binary gradient of water (A)
and acetonitrile (B) supplemented with 0.1% FA (CSF samples: 0min,
2% B; 3:30 min, 5% B; 137:30 min, 25% B; 168:30 min, 35% B; 182:30 min,
60% B; 185 min, 95% B; 200 min, 95% B; Gel fractions of glial
secretome: 0 min, 2% B; 3:30 min, 5% B; 48:30 min, 25% B; 59:30 min,
35% B; 64:30 min, 60% B).
CSF samples were analyzed on a Q-Exactive system using
a resolution of 70,000 for full mass spectrometry spectra. The 10
most intense peptide ions per spectrum were chosen for frag-
mentation using higher energy collisional dissociation (AGC target:
1E+5; NCE: 25%). A dynamic exclusion of 120 s was applied for
fragment ion spectra acquisition.
Full mass spectrometry spectra were acquired at a resolution of
60,000 (AGC target: 3E+6). The 10 most intense peptide ions per
spectrum were chosen for collision-induced dissociation within
the ion trap (AGC target: 1E+4; NCE: 35%; and activation Q: 0.25).
A dynamic exclusion of 90 s was applied for fragment ion spectra
acquisition.
LC–MS/MS data analysis
Database search and LFQ were performed with the software
MaxQuant (version 1.5.4.1, maxquant.org) using default settings (Cox
et al, 2014). A canonical database of the reviewed reference mouse
proteome (UniProt, download: June 8, 2016; 16,798 entries) was used
for database search. The false discovery rate for both peptides and
proteins was adjusted to <1% using a target and decoy approach
(concatenated forward/reverse database). The “match between
runs” option was enabled using a time window of 1.5 min. The LFQ
intensities were calculated based on unique peptides requiring at
least two ratio counts.
For relative quantiﬁcation of CSF samples, LFQ intensities were
log2 transformed and the average log2 ratio was calculated. At least
three quantiﬁcation values per group were required for statistical
analysis. A Student’s t test was applied to check for signiﬁcant
changes in protein abundance.
For relative quantiﬁcation of the glial secretome, the LFQ in-
tensity ratios of CpJ and vehicle-treated samples were calculated
separately for each experiment. At least three LFQ ratios were
required for statistical analysis. All LFQ ratios were log2 trans-
formed and a one-sample t test (μ0 = 0) was applied to check if the
average log2 LFQ ratio is different from zero.
For further data analysis, protein accessions were matched
against the subcellular location database of UniProt (membrane
[SL-0162]; cytoplasm [SL-0086]; mitochondrion [SL-0173]; secreted
[SL-0243]; nucleus [SL-0191]; cell membrane [SL-0039]; GPI-anchor
[SL-9902]; single-pass type I membrane protein [SL-9905]; single-
pass type II membrane protein [SL-9906]; single-pass type III
membrane protein [SL-9907]; single-pass type IVmembrane protein
[SL-9908]; and multi-pass membrane protein [SL-9909]). In addi-
tion, all proteins were matched against the UniProt keyword da-
tabase for glycoproteins [KW-0325].
Validation experiments in primary glia
Glia from Bace1−/− and Bace2−/− pups and their respective WT lit-
termates were cultured simultaneously. For each genotype, one vial
(representing two animals) was plated into a 10-cm dish (Fig S5B). At
conﬂuency, fresh serum-free medium was applied and collected
after 24 h. This experiment was repeated three times with in-
dependent cultures. In addition, WT, Bace1−/−, and Bace2/− glia were
cultured in two 10-cm dishes each until conﬂuency and treated with
CpJ or vehicle for 24 h in serum-free medium (Fig S5C). Again, two
animals per genotype per treatment were used and all experiments
were repeated at least three times. All collected media were
concentrated using the 30-kD Amicon Ultracel Centrifugal ﬁlters.
Cell lysates were prepared in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl,
2 mM EDTA, and 1% Triton X-100 supplemented with complete
protease inhibitor (Roche Applied Science). Cells were lysed for
20 min on ice and cleared by centrifugation at 14,000 g for 15 min.
Protein concentrations were measured using standard BCA assay
(Pierce).
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Western blotting
20 μg of total protein was separated by SDS–PAGE on 4–12% BisTris
gels and transferred onto nitrocellulose membranes. The mem-
branes were blocked in 5% milk prepared in TBS-0.1% Tween and
incubated in primary antibodies overnight at 4°C. The following
primary antibodies were used: rabbit monoclonal anti-BACE1 (Cell
Signaling, #5606, clone D10E5), rabbit polyclonal anti-BACE2 pro-
duced in-house, goat polyclonal anti-VCAM1 IgG (Thermo Fisher
Scientiﬁc, PA5-47029), goat polyclonal anti-DNER IgG (R&D Systems,
AF2254), mouse monoclonal anti-FGFR1 alpha antibody [M2F12]
(Abcam, ab829), mouse monoclonal anti-FLAG M2 (Sigma-Aldrich,
F3165), rabbit polyclonal anti-HA antibody (Clontech, 631207), and
mouse monoclonal anti-β-actin (Sigma-Aldrich, A5441). The fol-
lowing secondary antibodies were used: goat polyclonal anti-
mouse IgG-HRP conjugate (Biorad, 170-6516), goat polyclonal
anti-rabbit IgG-HRP conjugate (Biorad, 170-6515), rabbit polyclonal
anti-goat IgG-HRP conjugate (DAKO, P0449). Blots were developed
using the ImageQuant LAS 4000 mini machine (GE Healthcare) and
band intensities were quantiﬁed with AIDA image analyzer software
(Raytest). The levels of the full-length (FL) proteins were normalized
to actin levels.
COS-1 cell culture and transfections
COS-1 cells were seeded in 10% FBS supplemented DMEM/F-12 cell
culture medium in six-well plates. All cell culture medium and
supplements were purchased from Invitrogen. Transfections were
performed using the TransIT-LT1 Transfection Reagent (Mirus Bio
LLC) according to the manufacturer’s instructions. The following
constructs were used: mouse Bace1 and Bace2 in pSG5** vector as
in Dominguez et al (2005), except that Bace2 construct also con-
tained a C-terminal FLAG-tag for facilitated detection. Mouse Plxdc2
in pcDNA3.1 vector, tagged with HA-tag at the N-terminus and FLAG
at the C-terminus, was previously used (Dislich et al, 2015). FGFR1
plasmid in pWZL vector (Boehm et al, 2007) was purchased from
AddGene and re-cloned into the pSG5 vector by Gibson assembly.
Empty pcDNA3.1 vector was used as control in all overexpression
experiments. For validation of PLXDC2 and FGFR1 as BACE2 sub-
strates, the substrate constructs were transfected either alone or
together with either Bace1 or Bace2 constructs. Co-transfected
wells were treated with either 10 μM CpJ or vehicle; an empty vector
transfection was performed as control. Three independent trans-
fection experiments were performed for each substrate.
Mouse brain tissue collection and sample prep
Animals were euthanized using CO2 and decapitated. The brain was
subdissected, snap-frozen in liquid nitrogen, and stored at −80°C
until further analysis. Homogenates were prepared from cortices of
one hemisphere in 300 μl TBS buffer (50 mM Tris–HCl, pH 7.6, and
150 mM NaCl) supplemented with complete protease inhibitor
(Roche Applied Science) using a Teﬂon glass homogenizer. Fol-
lowing centrifugation at 14,000 g for 15 min, the supernatants were
placed in a fresh tube and ultracentrifuged at 70,000 g for 30 min
yielding the soluble TBS fractions. The remaining cell pellets were
lysed in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, and 1%
Triton X-100 supplemented with complete protease inhibitor
(Roche Applied Science) for 20 min on ice and cleared by centri-
fugation at 14,000 g for 15 min. Protein concentrations were
measured using standard BCA assay (Pierce) and the samples were
analyzed by Western blotting as described above to detect the shed
soluble fragments in TBS fraction and FL proteins in the total cell
lysates.
TNF treatment of glia cultures and mice
Primary glia cultures were prepared from Bace1−/− mice as de-
scribed above and two vials of frozen stock (representing four
animals) were seeded into six-well plates. The cells were treated
with recombinant murine TNF (10 ng/ml) or IL-1β (10 ng/ml) for 8 h
or 24 h. Three repeats of independent cultures were performed. For
inhibition experiments, the cells were pretreated with 10 μM CpJ or
vehicle overnight. The next morning, the cells were simultaneously
treated with 10 μM CpJ or vehicle in the presence of 10 ng/ml TNF or
CpJ or vehicle alone. Three repeats of independent cultures were
performed. Medium was processed and total cell lysates were
prepared as described above.
For in vivo experiments, WT, Bace1−/−, and Bace2−/− mice were
treated with PBS saline or 250 μg/kg TNF for 24 h; afterward CSF was
extracted as described above, the mice were euthanized, and the
brain was dissected and kept for analysis.
Statistical analysis
Statistical analysis for Western blot experiments was performed
using the GraphPad Prism Software. For validation experiments in
glia cells, immunoblot band intensity was normalized to that of
a vehicle-treated sample of each independent experiment and
paired t test was used to determine statistical differences. Analysis
of proteins in the CSF, TBS fraction, and total cell lysates of brain
homogenates from different genotypes was performed by one-way
ANOVA with Bonferroni post hoc test. VCAM1 measurement in the
CSF of WT mice treated with PBS or TNF was analyzed using un-
paired t test. VCAM1 in CSF frommice of different genotypes treated
with PBS or TNF was analyzed using two-way ANOVA with Tukey’s
multiple comparisons test. All Western blot quantiﬁcations are
presented as mean ± SD.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201800026.
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